Top 10 Pharmaceutical Companies at PSX- July 2025. Pakistan’s pharmaceutical sector continues to grow steadily, driven by an expanding population, increasing healthcare needs, and a strong focus on local medicine production. The industry’s impressive performance has made it a hotspot for both local and foreign investors.

In FY25, Pakistan’s pharmaceutical exports hit a 20-year high, growing by 34% and reaching $457 million. This milestone secured the industry a place among the top five fastest-growing export categories in the country.

Here’s a closer look at the top 10 pharmaceutical companies listed on the Pakistan Stock Exchange (PSX), ranked by market capitalisation as of July 24, 2025:

1. GlaxoSmithKline Pakistan Limited (PSX: GLAXO) – $438 Million

GlaxoSmithKline Pakistan is a leading multinational pharmaceutical company formed through the merger of SmithKline and French, Beecham, and Glaxo Wellcome in Pakistan. It operates two main business divisions:

• Prescription medicines and vaccines

• Consumer healthcare products, including OTC drugs, oral care, and nutritional products.

As of the latest filings, over 82% of GLAXO shares are held by S.R.One International B.V., while the general public owns around 6%.

2. Abbott Laboratories (Pakistan) Limited (PSX: ABOT) – $371 Million

Abbott Laboratories Pakistan has been a major player in the healthcare industry since 1948. The company manufactures, imports, and markets a wide range of medical and pharmaceutical products including:

• Pharmaceuticals

• Diagnostics

• Nutritional products

• Diabetes care solutions

Abbott’s strong global presence and innovation-driven approach contribute to its stable growth in Pakistan.

3. Haleon Pakistan Limited (PSX: HALEON) – $330 Million

Haleon Pakistan focuses on consumer healthcare and OTC products. The company is a subsidiary of Haleon Netherlands B.V., with Haleon plc as its ultimate parent.

Recently, Haleon announced a $12 million investment to expand its production capacity, primarily to boost Panadol manufacturing to meet growing domestic demand. In 2025, Qawi Naseer was appointed CEO, following the transfer of Farhan Muhammad Haroon to South Africa.

4. Highnoon Laboratories Limited (PSX: HINOON) – $202 Million

Highnoon Laboratories, established in 1984, manufactures and markets pharmaceutical and allied products. The company went public in 1995 and continues to grow in domestic and export markets.

In July 2025, the company appointed Tariq Wajid as its new chairman, reflecting its focus on strengthening corporate governance.

5. AGP Limited (PSX: AGP) – $189 Million

AGP Limited, formed in 2014, is involved in manufacturing, marketing, and exporting a wide range of pharmaceutical products. The company is part of the Aitkenstuart Pakistan group.

AGP has steadily grown its presence in both local and international markets, with a focus on quality and innovation.

6. The Searle Company Limited (PSX: SEARL) – $167 Million

Founded in 1965, SEARL manufactures and markets pharmaceutical, consumer health, and nutritional products. It is a subsidiary of International Brands (Private) Limited, which holds a 50.25% stake.

In 2025, the company appointed Tahir Ahmed as CEO, highlighting leadership renewal aimed at expanding market share.

7. Hoechst Pakistan Limited (PSX: HPL) – $105 Million

Previously known as Sanofi-aventis Pakistan, Hoechst Pakistan underwent a rebranding after a consortium led by Packages Limited acquired a majority stake in 2023.

The company is now expanding into international markets, with plans to establish a subsidiary in the UAE to benefit from a business-friendly environment.

8. Citi Pharma Limited (PSX: CPHL) – $66 Million

Citi Pharma, listed on the PSX in 2021, manufactures pharmaceutical and botanical products.

In 2024, it partnered with Mersi Farma of Indonesia to establish API manufacturing facilities and expand in the Southeast Asian nutraceutical market.

9. Macter International Limited (PSX: MACTER) – $62 Million

Established in 1992, Macter International focuses on pharmaceutical manufacturing and marketing. The company went public in 2011 and has continued to grow its product portfolio and market outreach.

10. Ferozsons Laboratories Limited (PSX: FEROZ) – $60 Million

Ferozsons, a pioneer in Pakistan’s pharma sector since 1954, produces pharmaceutical products and medical devices.

In 2025, the company announced it is exploring the acquisition of Barrett Hodgson Pakistan in collaboration with leading business groups, signaling a strategic move toward consolidation and growth.